MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 598179 | Name: Dilazep HCl
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dilazep HCl is a coronary vasodilator with some antiarrhythmic activity.

Chemical Structure

Dilazep HCl
CAS#20153-98-4 (HCl)

Theoretical Analysis

MedKoo Cat#: 598179

Name: Dilazep HCl

CAS#: 20153-98-4 (HCl)

Chemical Formula: C31H46Cl2N2O10

Exact Mass: 0.0000

Molecular Weight: 677.61

Elemental Analysis: C, 54.95; H, 6.84; Cl, 10.46; N, 4.13; O, 23.61

Price and Availability

Size Price Availability Quantity
50mg USD 550.00 2 Weeks
100mg USD 950.00 2 Weeks
200mg USD 1,650.00 2 Weeks
500mg USD 2,850.00 2 Weeks
1g USD 3,650.00 2 Weeks
2g USD 5,950.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
35898-87-4 (free base) 20153-98-4 (HCl)
Synonym
Dilazep dihydrochloride; Dilazep HCl; Cormelian; Comelian; AS 05; AS05; AS-05; NSC-760096; NSC760096; NSC 760096
IUPAC/Chemical Name
3-[4-[3-(3,4,5-trimethoxybenzoyl)oxypropyl]-1,4-diazepan-1-yl]propyl 3,4,5-trimethoxybenzoate;dihydrochloride
InChi Key
VILIWRRWAWKXRW-UHFFFAOYSA-N
InChi Code
InChI=1S/C31H44N2O10.2ClH/c1-36-24-18-22(19-25(37-2)28(24)40-5)30(34)42-16-8-12-32-10-7-11-33(15-14-32)13-9-17-43-31(35)23-20-26(38-3)29(41-6)27(21-23)39-4;;/h18-21H,7-17H2,1-6H3;2*1H
SMILES Code
O=C(OCCCN1CCN(CCCOC(C2=CC(OC)=C(OC)C(OC)=C2)=O)CCC1)C3=CC(OC)=C(OC)C(OC)=C3.[H]Cl.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Dilazep dihydrochloride is an inhibitor of adenosine uptake.
In vitro activity:
Therefore, these observations may suggest that the suppression of NO synthesis after dilazep treatment in RAW 264 cells is caused by the inhibition of TNF-alpha expression via adenosine receptors. Reference: J Pharmacol Sci. 2010;113(3):271-5. https://pubmed.ncbi.nlm.nih.gov/20647687/
In vivo activity:
Dilazep has been reported to inhibit edema formation in cerebral ischemia model of spontaneously hypertensive rats. These results suggest that dilazep prevents the ischemic damage of BBB, which may contribute to reduction of the brain edema. Reference: Naunyn Schmiedebergs Arch Pharmacol. 1992 Apr;345(4):485-8. https://pubmed.ncbi.nlm.nih.gov/1620248/
Solvent mg/mL mM comments
Solubility
Water 100.0 147.58
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 677.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
2. Nakatsuka R, Nozaki T, Shinohara M, Ohura K. Dilazep decreases lipopolysaccharide-induced nitric oxide and TNF-alpha synthesis in RAW 264 cells. J Pharmacol Sci. 2010;113(3):271-5. doi: 10.1254/jphs.09286sc. PMID: 20647687.1. Kawagoe J, Abe K, Ikuta J, Igarashi N, Shimizu S, Yamauchi Y, Kogure K. Effect of dilazep dihydrochloride against ischemia and reperfusion-induced disruption of blood-brain barrier in rats: a quantitative study. Naunyn Schmiedebergs Arch Pharmacol. 1992 Apr;345(4):485-8. doi: 10.1007/BF00176629. PMID: 1620248. 3. Zhang Y, Legare DJ, Geiger JD, Lautt WW. Dilazep potentiation of adenosine-mediated superior mesenteric arterial vasodilation. J Pharmacol Exp Ther. 1991 Sep;258(3):767-71. PMID: 1890619.
In vitro protocol:
1. Nakatsuka R, Nozaki T, Shinohara M, Ohura K. Dilazep decreases lipopolysaccharide-induced nitric oxide and TNF-alpha synthesis in RAW 264 cells. J Pharmacol Sci. 2010;113(3):271-5. doi: 10.1254/jphs.09286sc. PMID: 20647687.
In vivo protocol:
1. Kawagoe J, Abe K, Ikuta J, Igarashi N, Shimizu S, Yamauchi Y, Kogure K. Effect of dilazep dihydrochloride against ischemia and reperfusion-induced disruption of blood-brain barrier in rats: a quantitative study. Naunyn Schmiedebergs Arch Pharmacol. 1992 Apr;345(4):485-8. doi: 10.1007/BF00176629. PMID: 1620248. 2. Zhang Y, Legare DJ, Geiger JD, Lautt WW. Dilazep potentiation of adenosine-mediated superior mesenteric arterial vasodilation. J Pharmacol Exp Ther. 1991 Sep;258(3):767-71. PMID: 1890619.
1: Pirani R, Gruppillo P. Il dilazep [Dilazep]. G Ital Cardiol. 1980;10(10):1419-25. Italian. PMID: 7016654. 2: Deguchi H, Takeya H, Wada H, Gabazza EC, Hayashi N, Urano H, Suzuki K. Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes. Blood. 1997 Sep 15;90(6):2345-56. PMID: 9310485. 3: Zeng H, Liu S, Wang P, Qu X, Ji H, Wang X, Zhu X, Song Z, Yang X, Ma Z, Zhu H. Dilazep synergistically reactivates latent HIV-1 in latently infected cells. Mol Biol Rep. 2014 Nov;41(11):7697-704. doi: 10.1007/s11033-014-3662-z. Epub 2014 Aug 5. PMID: 25091947. 4: Nakatsuka R, Nozaki T, Shinohara M, Ohura K. Dilazep decreases lipopolysaccharide-induced nitric oxide and TNF-alpha synthesis in RAW 264 cells. J Pharmacol Sci. 2010;113(3):271-5. doi: 10.1254/jphs.09286sc. PMID: 20647687. 5: Playa H, Lewis TA, Ting A, Suh BC, Muñoz B, Matuza R, Passer BJ, Schreiber SL, Buolamwini JK. Dilazep analogues for the study of equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2). Bioorg Med Chem Lett. 2014 Dec 15;24(24):5801-5804. doi: 10.1016/j.bmcl.2014.10.026. Epub 2014 Oct 28. PMID: 25454272; PMCID: PMC5695681. 6: Tonini M, Perucca E, Manzo L, Marcoli M, D'Angelo L, Saltarelli P, Onori L. Dilazep: an inhibitor of adenosine uptake with intrinsic calcium antagonistic properties. J Pharm Pharmacol. 1983 Jul;35(7):434-9. doi: 10.1111/j.2042-7158.1983.tb04317.x. PMID: 6136584. 7: Sonoki K, Iwase M, Iino K, Ichikawa K, Yoshinari M, Ohdo S, Higuchi S, Iida M. Dilazep and fenofibric acid inhibit MCP-1 mRNA expression in glycoxidized LDL-stimulated human endothelial cells. Eur J Pharmacol. 2003 Aug 15;475(1-3):139-47. doi: 10.1016/s0014-2999(03)02109-5. PMID: 12954370. 8: Sakumura T, Fujii Z, Umemoto S, Murakami T, Kawata Y, Fujii K, Minami M, Sasaki K, Matsuzaki M. Dilazep, a nucleoside transporter inhibitor, modulates cell cycle progression and DNA synthesis in rat mesangial cells in vitro. Cell Prolif. 2000 Feb;33(1):19-28. doi: 10.1046/j.1365-2184.2000.00145.x. PMID: 10741641; PMCID: PMC6622404. 9: Gohda T, Makita Y, Shike T, Funabiki K, Shirato I, Tomino Y. Dilazep hydrochloride, an antiplatelet drug, inhibits lipopolysaccharide-induced mouse mesangial cell IL-6 secretion and proliferation. Kidney Blood Press Res. 2001;24(1):33-8. doi: 10.1159/000054203. PMID: 11174004. 10: Kawabata M, Haneda M, Wang T, Imai M, Takabatake T. Effects of a nucleoside transporter inhibitor, dilazep, on renal microcirculation in rats. Hypertens Res. 2002 Jul;25(4):615-21. doi: 10.1291/hypres.25.615. PMID: 12358150. 11: Zhang Y, Legare DJ, Geiger JD, Lautt WW. Dilazep potentiation of adenosine- mediated superior mesenteric arterial vasodilation. J Pharmacol Exp Ther. 1991 Sep;258(3):767-71. PMID: 1890619. 12: Zhou H. Dilazep and dipyridamole inhibit tissue factor expression on monocytes induced by IgG from patients with antiphospholipid syndrome. Acta Pharmacol Sin. 2004 Oct;25(10):1366-71. PMID: 15456541. 13: Haga N, Miura I, Fujisawa Y, Fukushi Y, Abiko Y. Effect of dilazep on decrease in myocardial pH during ischemia in dogs. Arzneimittelforschung. 1986 Jun;36(6):913-6. PMID: 3741523. 14: Marzilli M, Trivella MG, Levantesi D, Pelosi G, Dalle Vacche M, Taddei L, L'Abbate A. Effect of dilazep on coronary and systemic circulations. Pharmacology. 1985;31(2):82-7. doi: 10.1159/000138102. PMID: 4023048. 15: Chiba K, Hashizume H, Inagaki SI, Abiko Y. Dilazep inhibits binding of batrachotoxin to sodium channels in canine sarcolemmal vesicles. Arch Int Pharmacodyn Ther. 1995 Sep-Oct;330(2):138-50. PMID: 8861708. 16: Fujita S, Ishida Y, Izumi K, Moritoki H, Ohara M, Takei M. Potentiation by dilazep on the negative inotropic effect of adenosine on guinea-pig atria. Br J Pharmacol. 1980 Feb;68(2):343-9. doi: 10.1111/j.1476-5381.1980.tb10423.x. PMID: 7357212; PMCID: PMC2043930. 17: Poggesi L, Masotti G, Serneri GG, Carnovali M. Intravenous dilazep reduces blood pressure and peripheral vascular resistance in humans. J Clin Pharmacol. 1988 Jan;28(1):43-7. doi: 10.1002/j.1552-4604.1988.tb03099.x. Erratum in: J Clin Pharmacol 1988 Apr;28(4):326. PMID: 3280614. 18: Thorn JA, Jarvis SM. Adenosine transporters. Gen Pharmacol. 1996 Jun;27(4):613-20. doi: 10.1016/0306-3623(95)02053-5. PMID: 8853292. 19: Persson P, Fasching A, Pihl L, Palm F. Adenosine reuptake inhibition reduces diabetes-induced glomerular hyperfiltration via the adenosine A2a receptor. Am J Physiol Regul Integr Comp Physiol. 2023 Oct 1;325(4):R337-R343. doi: 10.1152/ajpregu.00278.2022. Epub 2023 Jul 24. PMID: 37486069. 20: Gati WP, Paterson AR. Interaction of [3H]dilazep at nucleoside transporter- associated binding sites on S49 mouse lymphoma cells. Mol Pharmacol. 1989 Jul;36(1):134-41. PMID: 2747624.